Potassium Binders

Risks & contraindications

Comparisons

Evidence quality

Highlighted claims

• Sodium polystyrene sulfonate is FDA-approved as a potassium binder but is limited by gastrointestinal adverse effects including nausea, vomiting, and reports of colonic necrosis. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• The ENERGIZE trial of sodium zirconium cyclosilicate in the emergency department also found no difference in its primary efficacy endpoint and ended prematurely due to slow enrolment. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Haemodialysis removes potassium effectively but is invasive and may not be immediately available in the emergency department. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• Demonstrating potassium binder efficacy in the emergency department is difficult because stabilising treatments produce transient potassium shifts and emergency department turnover is rapid. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department
• The REDUCE pilot study showed a trend toward lower serum potassium and fewer potassium-lowering agents with patiromer but was underpowered for statistical significance. — Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department